1. Home
  2. CAC vs OMER Comparison

CAC vs OMER Comparison

Compare CAC & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CAC
  • OMER
  • Stock Information
  • Founded
  • CAC 1875
  • OMER 1994
  • Country
  • CAC United States
  • OMER United States
  • Employees
  • CAC N/A
  • OMER 198
  • Industry
  • CAC Major Banks
  • OMER Biotechnology: Pharmaceutical Preparations
  • Sector
  • CAC Finance
  • OMER Health Care
  • Exchange
  • CAC Nasdaq
  • OMER Nasdaq
  • Market Cap
  • CAC 616.5M
  • OMER 530.2M
  • IPO Year
  • CAC 1997
  • OMER 2009
  • Fundamental
  • Price
  • CAC $44.80
  • OMER $9.15
  • Analyst Decision
  • CAC Hold
  • OMER Buy
  • Analyst Count
  • CAC 3
  • OMER 4
  • Target Price
  • CAC $46.67
  • OMER $22.50
  • AVG Volume (30 Days)
  • CAC 81.6K
  • OMER 1.1M
  • Earning Date
  • CAC 01-28-2025
  • OMER 11-13-2024
  • Dividend Yield
  • CAC 3.77%
  • OMER N/A
  • EPS Growth
  • CAC N/A
  • OMER N/A
  • EPS
  • CAC 3.20
  • OMER N/A
  • Revenue
  • CAC $168,756,000.00
  • OMER N/A
  • Revenue This Year
  • CAC N/A
  • OMER N/A
  • Revenue Next Year
  • CAC $30.91
  • OMER N/A
  • P/E Ratio
  • CAC $13.93
  • OMER N/A
  • Revenue Growth
  • CAC N/A
  • OMER N/A
  • 52 Week Low
  • CAC $28.62
  • OMER $2.61
  • 52 Week High
  • CAC $50.07
  • OMER $13.60
  • Technical
  • Relative Strength Index (RSI)
  • CAC 58.84
  • OMER 48.28
  • Support Level
  • CAC $43.30
  • OMER $8.82
  • Resistance Level
  • CAC $44.78
  • OMER $11.26
  • Average True Range (ATR)
  • CAC 1.07
  • OMER 0.86
  • MACD
  • CAC 0.37
  • OMER -0.18
  • Stochastic Oscillator
  • CAC 90.04
  • OMER 29.47

About CAC Camden National Corporation

Camden National Corporation is a banking solutions provider in the United States. Its core business is providing commercial banking products to individuals and corporates. Its consumer and commercial banking services entail services such as loans and deposits, savings and online banking, treasury management solutions and non-profit products to consumer, institutional, municipal, non-profit and commercial customers. The company also offers investment management and fiduciary services.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: